FDA to remove ingredient from cold medicines after data shows it does not work
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
Atlanta Journal-Constitution6h
FDA proposes pulling decongestants from shelves over one ingredient
For some products, it is the only ingredient, the FDA said in a news release issued Thursday. Others contain oral phenylephrine and acetaminophen, dextromethorphan or another active ingredient.
FDA to pull common but ineffective cold medicine from market
The FDA says oral phenylephrine, used in many over-the-counter cough and cold medicines, "is not effective as a nasal ...
BioPharma Dive2h
FDA approves new CAR-T competitor to Gilead’s Tecartus
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
FDA proposes ending use of decongestant found in many cold, allergy medicines
An extensive review determined that the ingredient, oral phenylephrine, doesn’t actually relieve nasal congestion.
Cure Today4h
FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma
If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
Liam Payne showed me new music he was planning to release, ‘drug dealer’ suspect says as he denies wrongdoing
A SUSPECT under investigation in connection with Liam Payne’s tragic death has claimed the One Direction star gave him a ...
Meet NYC’s ‘worst drug dealer’ — who has been arrested 20 times but keeps getting let out
One alleged drug dealer has been arrested 20 times in two years for dealing crack, heroin, fentanyl and other drugs in ...
FDA says commonly used decongestant 'not effective,' proposes removal
The U.S. Food and Drug Administration has determined commonly used oral phenylephrine is "not effective" and has proposed its ...
FiercePharma4h
Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod
In the FELIX study, the treatment showed low levels of cytokine release syndrome (CRS) with 3% grade 3 events and no grade 4 or 5 events. Like other CAR-T products, Aucatzyl still comes with an FDA ...
Cure Today2d
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Medscape2d
FDA Approved Obe-cel, a Novel CD19 CAR T Product for ALL
Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.